Table 2.
Antitumor activity against residual leukemic stem and progenitor cells |
Postponement of disease relapse thereby buying time for the genesis of a GVL effect |
Manipulation of the kinetics of disease relapse permitting postponement of DLI to a later time posttransplant when the risk of severe GVHD is reduced |
Pharmacologic manipulation of a GVL response using agents such as azacitidine or sorafenib |